Orion Oyj Logo

Orion Oyj

Develops and manufactures human/vet pharma, APIs, and generics for global markets.

ORNAV | HE

Overview

Corporate Details

ISIN(s):
FI0009014377 (+1 more)
LEI:
74370029VAHCXDR7B745
Country:
Finland
Address:
Orionintie 1, FI-02200 ESPOO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Orion Oyj is a globally operating Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs). With a history of over a century, the company focuses on 'building well-being' by translating scientific research into novel therapies and treatments. Orion's research and development efforts are primarily concentrated on specific therapeutic areas, including oncology and pain management. In addition to its portfolio of proprietary drugs, the company also produces generic products and self-care items. Its subsidiary, Fermion, is a key manufacturer of APIs for both Orion and external customers worldwide. Orion also engages in contract manufacturing and the development of diagnostic tests.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-28 11:00
Quarterly Report
Orion-konsernin osavuosikatsaus tammi-syyskuu 2025
Finnish 22.8 KB
2025-10-28 11:00
Quarterly Report
Orion Group Interim Report January-September 2025
English 22.5 KB
2025-10-24 08:00
Share Issue/Capital Change
49 164 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi
Finnish 2.7 KB
2025-10-24 08:00
Share Issue/Capital Change
49,164 Orion Corporation A shares converted into B shares
English 2.8 KB
2025-09-30 08:00
Major Shareholding Notification
Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoitus (Black…
Finnish 5.6 KB
2025-09-30 08:00
Major Shareholding Notification
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Mark…
English 5.7 KB
2025-09-26 15:30
Major Shareholding Notification
Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoitus (Black…
Finnish 5.6 KB
2025-09-26 15:30
Major Shareholding Notification
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Mark…
English 5.7 KB
2025-09-19 08:00
Share Issue/Capital Change
80 802 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi
Finnish 2.7 KB
2025-09-19 08:00
Share Issue/Capital Change
80,802 Orion Corporation A shares converted into B shares
English 2.8 KB
2025-08-20 08:00
Share Issue/Capital Change
337 000 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi
Finnish 2.7 KB
2025-08-20 08:00
Share Issue/Capital Change
337,000 Orion Corporation A shares converted into B shares
English 2.8 KB
2025-08-08 08:30
Director's Dealing
Orion Oyj: Johtohenkilöiden liiketoimet - Juhani Kankaanpää
Finnish 4.9 KB
2025-08-08 08:30
Director's Dealing
Orion Corporation: Managers' transactions - Juhani Kankaanpää
English 4.8 KB
2025-08-04 15:10
Director's Dealing
Orion Oyj: Johtohenkilöiden liiketoimet - Satu Ahomäki
Finnish 3.5 KB

Automate Your Workflow. Get a real-time feed of all Orion Oyj filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Orion Oyj

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Orion Oyj via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea 179530
Advicenne Logo
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France ALDVI
AegirBio AB Logo
Develops user-friendly, saliva-based tests for health monitoring & therapeutic drug monitoring.
Sweden AEGIR
Aelis Farma Logo
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France AELIS
AFC-HD AMS Life Science Co.,Ltd. Logo
An OEM of health foods, supplements, and cosmetics, managing the full value chain from R&D to sales.
Japan 2927
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark ALK
Alkaloid AD Logo
Manufactures pharmaceuticals, cosmetics, and herbal products for professionals and consumers.
North Macedonia ALK
ALLERGY THERAPEUTICS PLC Logo
Develops innovative, aluminum-free allergy immunotherapy vaccines for the European market.
United Kingdom AGY
Alligator Bioscience Logo
Develops immuno-oncology antibody drugs to activate the immune system against hard-to-treat cancers.
Sweden ATORX

Talk to a Data Expert

Have a question? We'll get back to you promptly.